Thirty cases of a primary malignant lymphoma (ML) have been studied clinicopathologically and immunohistochemically. The average age of the patients was 59.1 years, and the ratio of males to females was 1:1.7. According to the Kiel classification of MLs, 53.3% had a low grade malignancy and 46.7% were a high grade malignancy. Therefore, the number with a low or a high grade malignancy was almost equal. Most of the low grade malignancies were ML, centroblastic centrocytic, and most of the high grade malignancies were ML, lymphoblastic. From histopathological and immunohistochemical studies, most cases were considered to be of B-cell origin and two thirds of the cases were regarded as being of a follicular center cell origin. Prognosis was better than that of other MLs. Finally, MLs of the thyroid were found combined more frequently with chronic thyroiditis of the Hashimoto type than malignant epithelial neoplasms.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: In TALAPRO-2, the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor-signaling inhibitor enzalutamide improved radiographic progression-free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63; 95% CI, 0.51-0.
View Article and Find Full Text PDFCase report: High-grade hidradenocarcinoma of the chest wall with insights from F-FDG PET/CT imaging and a review of the literature.
Front Oncol
December 2024
Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Hidradenocarcinoma (HAC) is a rare neoplasm that typically occurs in the head and neck region but seldom affects the chest wall. Histopathology and immunohistochemistry remain essential for diagnosing HAC, although their clinical utility in determining metastasis can be limited. Given the pathological rarity and histopathological heterogeneity of HAC, we report a case demonstrating the utility of positron emission tomography/computed tomography (PET/CT) combined with immunohistochemical examination for the accurate diagnosis and staging of HAC.
View Article and Find Full Text PDFImpact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.
Front Immunol
December 2024
German Cancer Consortium (DKTK), Partner site Frankfurt/Mainz, a partnership between DKFZ and University Medical Center Frankfurt, Frankfurt, Germany.
Introduction: Posttransplant cyclophosphamide (PTCy) has revolutionized the landscape of human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (haplo-HCT), providing a pivotal therapeutic option for patients with hematological malignancies who lack an HLA-matched donor.
Methods: In this retrospective analysis involving 54 adult patients undergoing PTCy-based haplo-HCT, we evaluated the impact of inhibitory killer immunoglobulin-like receptor (KIR)/HLA mismatch, alongside patient, donor, and transplant factors, on clinical outcomes within a homogeneous cohort characterized by a myeloablative conditioning regimen and bone marrow graft.
Results: With a median follow-up of 73.
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study.
J Hematol Oncol
December 2024
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Co-inhibition of immune checkpoints lymphocyte-activation gene 3 (LAG-3) and PD-1 is believed to enhance cancer immunotherapy through synergistic effects. Herein, we evaluate the safety and efficacy of IBI110 (anti-LAG-3 antibody) with sintilimab (an anti-PD-1 antibody) in Chinese patients with advanced solid tumors.
Methods: In this open-label phase I study, phase Ia dose escalation of IBI110 monotherapy and phase Ib combination dose escalation of IBI110 plus sintilimab were conducted in patients with advanced solid tumors.
Extensive cervical lesion and treatment outcomes in women with HIV/HPV co-infection.
AIDS Res Ther
December 2024
Jennifer Tiu, ACTG Network Coordinating Center, Bethesda, USA.
Background: Cervical cancer is a common cancer worldwide, with > 85% of deaths occurring in Lower- and Middle-Income Countries where resources for screening programs are limited. Women living with HIV (WLHIV) are at increased risk. HPV test-and-treat is a screening strategy where women with HPV are offered ablative treatment of the cervix to reduce the risk of invasive cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!